We assessed the prevalence and impact of COVID-19 among multiple sclerosis (MS) patients across Europe by leveraging participant data collected as part of the ongoing EU IMI2 RADAR-CNS major programme aimed at finding new ways of monitoring neurological disorders using wearable devices and smartphone technology. In the present study, 399 patients of RADAR-MS have been included (mean age 43.9 years, 60.7% females) with 87/399 patients (21.8%) reporting major symptoms suggestive of COVID-19. A trend for an increased risk of COVID-19 symptoms under alemtuzumab and cladribine treatments in comparison to injectables was observed. Remote monitoring technologies may support health authorities in monitoring and containing the ongoing pandemic.

我们通过利用正在进行的EU IMI2 RADAR-CNS主要计划的一部分收集的参与者数据来评估欧洲多发性硬化症（MS）患者中COVID-19的患病率和影响，该计划旨在寻找使用可穿戴设备和智能手机监测神经系统疾病的新方法技术。在本研究中，纳入了399例RADAR-MS患者（平均年龄43.9岁，女性60.7％），其中87/399例患者（21.8％）报告了提示COVID-19的主要症状。观察到与注射剂相比，在阿仑单抗和克拉屈滨治疗下COVID-19症状风险增加的趋势。远程监控技术可以支持卫生当局监控和控制正在进行的大流行。